Meningococcal group A, C, Y and W-135 conjugate vaccine.
In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11-55 years.
Harrison
Lee H
LH
Infectious Diseases Epidemiology Research Unit, University of Pittsburgh Graduate School of Public Health and School of Medicine, Pittsburgh, Pennsylvania 15101, USA. lharriso@edc.pitt.edu
Mohan
Nitin
N
Kirkpatrick
Peter
P
D000293:Adolescent; D000328:Adult; D002648:Child; D017277:Drug Approval; D006801:Humans; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology*; D008875:Middle Aged; D038381:Neisseria meningitidis, Serogroup A / Q000276:immunology*; D038542:Neisseria meningitidis, Serogroup C / Q000276:immunology*; D038582:Neisseria meningitidis, Serogroup W-135 / Q000276:immunology*; D038581:Neisseria meningitidis, Serogroup Y / Q000276:immunology*; D018074:Vaccines, Conjugate
D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate